Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Cancer Res. 2014 Nov 6;74(24):7371–7382. doi: 10.1158/0008-5472.CAN-14-0794

Figure 1.

Figure 1

Overexpression of Mig-6 retards endometrial cancer progression in conditional uterine ablation of Pten. (A) Mig-6overPtend/d mice exhibit significantly increased survival time. Survival time in control (black), Mig-6over (black), Ptend/d (blue), and Mig-6overPtend/d (green) mice. p<0.0001 (between Ptend/d and Mig-6overPtend/d), n=20 per genotype. (B) The ratio of uterine weight to body weight in control, Mig-6overPtend/d, Ptend/d and Mig-6overPtend/d mice at 3 months of age. The results represent the mean ± SEM. * p<0.05. (C) The uterine morphology in Control, Mig-6over, Ptend/d and Mig-6overPtend/d mice at 2 months of age (a, b, c and d) and 3 months of age (e, f, g and h). (D) H&E staining of Ptend/d and Mig-6overPtend/d mice at 3 months of age.